Introducing vasomotor symptoms
‘VMS breakthroughs’ is a four-article series covering key topics and developments in management of menopause-related vasomotor symptoms (VMS). It includes:
- The burdens of VMS, focusing on the adverse impacts of VMS on women’s quality of life
- An overview of the mental health impacts of VMS and the treatment options available
- The role of oestradiol withdrawal in the pathophysiology of VMS and the treatments available to alleviate the impact of changing hormone levels
- A look to the future of VMS management, putting the focus on emerging therapies and how they may address unmet needs in VMS and menopause
Alongside the articles, view expert interviews featuring Dr Juliana Kling (Mayo Clinic, Scottsdale, Arizona, USA) and Dr Lisa Larkin (Concierge Medicine, Cincinnati, Ohio, USA). And complete short quizzes throughout this article series to access exclusive content, including ‘A psychologist's perspective’, in which Dr Sheryl Kingsberg (University Hospitals of Cleveland, Ohio, USA) takes a closer look at the psychological implications of VMS.
Meet the experts
Dr Juliana (Jewel) Kling
Dr Kling is a Professor of Medicine, Chair of the Division of Women’s Health Internal Medicine, Assistant Director of the Mayo Clinic Women’s Health Center, and Dean of the Mayo Clinic Alix School of Medicine AZ campus at the Mayo Clinic in Scottsdale, Arizona, USA. Her clinical and research interests are in menopause, sexual health, LGBT care, and education, as well as in efforts to expand the discipline of sex- and gender-specific medicine.
Disclosures: AiCME, Contemporary OB/GYN, Elsevier, Evolve Medical Education, Let’s Talk Menopause, and Paradise Valley Country Club.
Dr Sheryl Kingsberg
Dr Kingsberg is the Division Chief of Behavioural Medicine at MacDonald Women’s Hospital/University Hospitals Cleveland Medical Center and Professor in Reproductive Biology, Urology and Psychiatry at Case Western Reserve University, Cleveland, Ohio, USA. Her areas of specialisation include female sexual disorders, menopause, pregnancy and postpartum mood disorders, and psychological aspects of infertility.
Disclosures: Astellas, Alloy, Bayer, Daré Bioscience, Freya, Madorra, Materna Medical, Ms. Medicine, Palatin Technologies, Pfizer, ReJoy, Reunion Neuroscience, Sprout, Strategic Science Technologies, University Hospitals Cleveland Medical Center, and Vella.
Dr Lisa Larkin
Dr Lisa Larkin is President of the Menopause Society, a board-certified internist, and Founder and Executive Director of the Cincinnati Sexual Health Consortium, a nonprofit organisation formed to improve sexual health and wellness in Cincinnati, USA. Dr Larkin was Associate Professor and Division Director of Midlife Women’s Health and Primary Care at the University of Cincinnati College of Medicine.
Disclosures: AbbVie, Astellas, Avion, Esperion, Grail, Johnson & Johnson, Mayne Pharma, Pharmavite, Pfizer, Scynexis, Sprout, Solv Wellness, and Therapeutics MD.
Understanding the burden of VMS on women's lives
The burden of vasomotor symptoms can impact the lives of women in various ways and take a significant toll on quality of life.
Mental health implications of VMS
Vasomotor symptoms have significant and negative impacts on the mental wellbeing of menopausal women.
Oestradiol withdrawal in the pathophysiology of VMS
Declining oestradiol levels (‘oestradiol withdrawal’) rather than low oestrogen alone could be part of the pathogenesis of VMS.
Advances in vasomotor symptom treatments
Read about newly approved and investigational treatments for vasomotor symptoms, including fezolinetant, elinzanetant, and estetrol.
of interest
are looking at
saved
next event
Developed independently by EPG Health, which received an educational grant from Heartbeat, on behalf of Astellas, to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.